PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
30-Apr-2025 Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025 Domain Therapeutics
30-Apr-2025 Update on CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer AstraZeneca
30-Apr-2025 Fixed-duration Calquence-based regimens recommended for approval in the EU by CHMP for 1st-line chronic lymphocytic leukaemia AstraZeneca
30-Apr-2025 Rare Disease Day 2025: Rally for Rare Event Recap Worldwide CLinical Trials
30-Apr-2025 Addressing Uncertainty in Survival Studies Cytel
30-Apr-2025 Labcorp Announces 2025 First Quarter Results Labcorp
30-Apr-2025 Novavax Appoints Charles Newton to Board of Directors Novavax
30-Apr-2025 Guru Ramamurthy appointed as new CFO for Bayer’s Crop Science Division Bayer
30-Apr-2025 Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Sanofi
30-Apr-2025 Johnson & Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) Johnson & Johnson
30-Apr-2025 CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings Roche
30-Apr-2025 Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer Roche
30-Apr-2025 Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis Gilead
30-Apr-2025 Breaking new ground in mental health research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience launch first of its kind study investigating the day-to-day experience of patients with psychiatric disorders Boehringer Ingelheim
30-Apr-2025 GSK makes strong start to 2025 with growth in sales, profits and earnings GSK
30-Apr-2025 Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers Nouscom
30-Apr-2025 Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma Microbiotica
25-Apr-2025 Olympus Appoints New CEO - Names Bob White Representative Executive Officer, President, Chief Executive Officer and a new Director candidate Olympus Corporation
24-Apr-2025 Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025 Heidelberg Pharma AG
24-Apr-2025 OXB Named Among UK’s Best Employers by Financial Times in 2025 OXB